Trials / Unknown
UnknownNCT05776043
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure (EMPATHY) - a Phase III Trial.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,364 (estimated)
- Sponsor
- Medical University of Warsaw · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
National, multicenter, randomized, double-blind, parallel-group, stratified by SGLT-2 inhibitor type, placebo-controlled trial, - a Phase III study. Primary objective of the study is to investigate the impact of SGLT-2 inhibitors (Empagliflozin and Dapagliflozin) on clinical endpoints in patients hospitalized with acute/decompensated HF.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin 10 MG | once daily for 6 or 9 months |
| DRUG | Dapagliflozin 10 MG | once daily for 6 or 9 months |
| DRUG | Placebo | once daily for 3 months |
Timeline
- Start date
- 2022-03-15
- Primary completion
- 2024-09-30
- Completion
- 2025-12-31
- First posted
- 2023-03-20
- Last updated
- 2023-03-20
Locations
1 site across 1 country: Poland
Source: ClinicalTrials.gov record NCT05776043. Inclusion in this directory is not an endorsement.